Constitutive NF-κB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells

Blood

Volumn 97, Issue 9, 2001, Pages 2798-2807

  Hinz, Michael ^a,b,c   Löser, Peter ^a,b,c   Mathas, Stephan ^a,b,c   Krappmann, Daniel ^a,b,c   Dörken, Bernd ^a,b,c   Scheidereit, Claus ^a,b,c  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b HepaVec AG   (Germany)

^c Section of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INHIBITOR; CD40 ANTIGEN; CD86 ANTIGEN; CYCLIN D2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL X; PROTEIN BFL 1; PROTEIN C IAP2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG; CD86 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN;

ADENOVIRUS; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; GENE TARGETING; HODGKIN DISEASE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; REED STERNBERG CELL; TRANSCRIPTION REGULATION; TUMOR GROWTH; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, CD86; APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; MEMBRANE GLYCOPROTEINS; NF-KAPPA B; REED-STERNBERG CELLS;

EID: 0035324928     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.9.2798     Document Type: Article

References (82)

1. Baeuerle PA, Baltimore D. NF-κB: ten years after. Cell. 1996;87:13-20.
2. Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649-683.
3. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-κB. Annu Rev Cell Biol. 1994;10:405-455.
4. Wulczyn FG, Krappmann D, Scheidereit C. The NF-κB/Rel and IκB gene families: mediators of immune response and inflammation. J Mol Med. 1996;74:749-769.
5. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999;18:6938-6947.
6. Sonenshein GE. Rel/NF-κB transcription factors and the control of apoptosis. Semin Cancer Biol. 1997;8:113-119.
7. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225-260.
8. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene. 1999;18:6910-6924.
9. May MJ, Ghosh S. Rel/NF-κB and IκB proteins: an overview. Semin Cancer Biol. 1997;8:63-73.
10. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-κB/IκB family: intimate tales of association and dissociation. Genes Dev. 1995;9:2723-2735.
11. Zandi E, Karin M. Bridging the gap: composition, regulation, and physiological function of the IκB kinase complex. Mol Cell Biol. 1999;19:4547-4551.
12. Hatada EN, Krappmann D, Scheidereit C. NF-κB and the innate immune response. Curr Opin Immunol. 2000;12:52-58.
13. Gilmore TD. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene. 1999;18:6925-6937.
14. Cahir McFarland ED, Izumi KM, Mosialos G. Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-κB. Oncogene, 1999;18:6959-6964.
15. Sun SC, Ballard DW. Persistent activation of NF-κB by the Tax transforming protein of HTLV-1: hijacking cellular IκB kinases. Oncogene. 1999;18:6948-6958.
16. Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-κB and Oct-2 is a common feature of cultured Hodgkin/Reed-Stemberg cells. Blood. 1996;87:4340-4347.
17. Staudt LM. The molecular and cellular origins of Hodgkin's disease. J Exp Med. 2000;191:207-212.
18. Hsu SM, Hsu PL. The nature of Reed-Sternberg cells: phenotype, genotype, and other properties. Crit Rev Oncog. 1994;5:213-245.
19. Kaufman D, Longo DL. Hodgkin's disease. Crit Rev Oncol Hematol. 1992;13:135-187.
20. Kuppers R, Hansmann ML, Rajewsky K. Clonality and germinal centre B-cell derivation of Hodgkin/Reed-Sternberg cells in Hodgkin's disease. Ann Oncol. 1998;9(suppl 5):17-20.
21. Kanzler H, Hansmann ML, Kapp U, et al. Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient. Blood. 1996;87:3429-3436.
22. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IκBa gene in Hodgkin's disease suggest a tumour suppressor role for IκBa. Oncogene. 1999;18:3063-3070.
23. Emmerich F, Meiser M, Hummel M, et al. Overexpression of IκBa without inhibition of NF-κB activity and mutations in the IκBa gene in Reed-Sternberg cells. Blood. 1999;94:3129-3134.
24. Jungnickel B, Staratschek-Jox A, Bräuninger A, et al. Clonal deleterious mutations in the IκBa gene in the malignant cells in Hodgkin's lymphoma. J Exp Med. 2000;191:395-402.
25. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dörken B, Scheidereit C. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene. 1999;18:943-953.
26. Wood KM, Roff M, Hay RT. Defective IκBalpha in Hodgkin cell lines with constitutively active NF-κB. Oncogene. 1998;16:2131-2139.
27. Sylla BS, Hung SC, Davidson DM, et al. Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-κB through a pathway that includes the NF-κB-inducing kinase and the IκB kinases IKKα and IKKβ. Proc Natl Acad Sci U S A. 1998;95:10106-10111.
28. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 1982;299:65-67.
29. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848-858.
30. O'Grady JT, Stewart S, Lowrey J, Howie SE, Krajewski AS. CD40 expression in Hodgkin's disease. Am J Pathol. 1994;144:21-26.
31. Biswas P, Smith CA, Goletti D, Hardy EC, Jackson RW, Fauci AS. Cross-linking of CD30 induces HIV expression in chronically infected T cells. Immunity. 1995;2:587-596.
32. Carbone A, Gloghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood. 1995;85:780-789.
33. McDonald PP, Cassatella MA, Bald A, et al. CD30 ligation induces nuclear factor-kappa B activation in human T cell lines. Eur J Immunol. 1995;25:2870-2876.
34. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100:2961-2969.
35. Chartier C, Degryse E, Gantzer M, Dieterlé A, Pavirani A, Methali M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol. 1996;70:4805-4810.
36. Krappmann D, Wulczyn FG, Scheidereit C. Different mechanisms control signal-induced degradation and basal turnover of the NF-κB inhibitor IκBα in vivo. EMBO J. 1996;15:6716-6726.
37. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A. 1994;91:8802-8806.
38. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977;36:59-74.
39. Sandig V, Löser P, Lieber A, Kay MA, Strauss M. HBV-derived promoters direct liver-specific expression of an adenovirally transduced LDL receptor gene. Gene Ther. 1996;3:1002-1009.
40. Rudert F, Visser E, Forbes L, Lindridge E, Wang Y, Watson J. Identification of a silencer, enhancer, and basal promoter region in the human CD95 (Fas/APO-1) gene. DNA Cell Biol. 1995;14:931-937.
41. Hirano F, Tanaka H, Hirano Y, et al. Functional interference of Sp1 and NF-κB through the same DNA binding site. Mol Cell Biol. 1998;18:1266-1274.
42. Wulczyn FG, Krappmann D, Scheidereit C. Signal-dependent degradation of IκBα is mediated by an inducible destruction box that can be transferred to NF-κB, bcl-3 or p53. Nucleic Acids Res. 1998;26:1724-1730.
43. Naumann M, Wulczyn FG, Scheidereit C. The NF-κB precursor p105 and the proto-oncogene product Bcl-3 are IκB molecules and control nuclear translocation of NF-κB. EMBO J. 1993;12:213-222.
44. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19:5785-5799.
45. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-κB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 1999;19:2690-2698.
46. Stamenkovic I, Clark EA, Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J. 1989;8:1403-1410.
47. Speiser DE, Lee SY, Wong B, et al. A regulatory role for TRAF1 in antigen-induced apoptosis of T cells. J Exp Med. 1997;185:1777-1783.
48. Teramoto N, Pokrovskaja K, Szekely L, et al. Expression of cyclin D2 and D3 in lymphoid lesions. Int J Cancer. 1999;81:543-550.
49. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323-330.
50. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
51. Strauss M, Lukas J, Bartek J. Unrestricted cell cycling and cancer. Nat Med. 1995;1:1245-1246.
52. Brooks AR, Shiffman D, Chan CS, Brooks EE, Milner PG. Functional analysis of the human cyclin D2 and cyclin D3 promoters. J Biol Chem. 1996;271:9090-9099.
53. Spender LC, Cannell EJ, Hollyoake M, et al. Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus. J Virol. 1999;73:4678-4688.
54. Brand K, Klocke R, Possling A, Paul D, Strauss M. Induction of apoptosis and G2/M arrest by infection with replication-deficient adenovirus at high multiplicity of infection. Gene Ther. 1999;6:1054-1063.
55. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
56. Wu H, Lozano G. NF-kappa B activation of p53: a potential mechanism for suppressing cell growth in response to stress. J Biol Chem. 1994;269:20067-20074.
57. Grumont RJ, Rourke IJ, Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev. 1999;13:400-411.
58. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis. Genes Dev. 1999;13:382-387.
59. Chen C, Edelstein LC, Gelinas C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol. 2000;20:2687-2695.
60. Hong S-Y, Yoon W-H, Park J-H, Kang S-G, Ahn J-H, Lee TH. Involvement of two NF-κB binding elements in tumor necrosis factor α-, CD40-, and Epstein-Barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene. J Biol Chem. 2000;275:18022-18028.
61. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E. NF-κB inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A. 2000;97:6055-6060.
62. Schlaifer D, March M, Krajewski S, et al. High expression of the bcl-x gene in Reed-Sternberg cells of Hodgkin's disease. Blood. 1995;85:2671-2674.
63. Messineo C, Jamerson MH, Hunter E, et al. Gene expression by single Reed-Sternberg cells: pathways of apoptosis and activation. Blood. 1998;91:2443-2451.
64. Chu WS, Aguilera NS, Wei MQ, Abbondanzo SL. Antiapoptotic marker Bcl-X(L), expression on Reed-Sternberg cells of Hodgkin's disease using a novel monoclonal marker, YTH-2H12. Hum Pathol. 1999;30:1065-1070.
65. Dürkop H, Foss HD, Demel G, Klotzbach H, Hahn C, Stein H. Tumor necrosis factor receptor-associated factor1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr virus-transformed lymphoid cells. Blood. 1999;93:617-623.
66. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322-1326.
67. Vander Heiden MG, Chaandel NS, Williamson EK, Schumacker PT, Thompson CB. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell. 1997;91:627-637.
68. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene. 1999;18:6853-6866.
69. Lane P. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86. Ann N Y Acad Sci. 1997;815:392-400.
70. Li J, Liu Z, Jiang S, Cortesini R, Lederman S, Suciu-Foca N. T suppressor lymphocytes inhibit NF-κB-mediated transcription of CD86 gene in APC. J Immunol. 1999;163:6386-6392.
71. Van Gool SW, Delabie J, Vandenberghe P, Coorevits L, De Wolf-Peeters C, Ceuppens JL. Expression of B7-2 (CD86) molecules by Reed-Sternberg cells of Hodgkin's disease. Leukemia. 1997;11:846-851.
72. Nozawa Y, Wakasa H, Abe M. Costimulatory molecules (CD80 and CD86) on Reed-Sternberg cells are associated with the proliferation of background T cells in Hodgkin's disease. Pathol Int. 1998;48:10-14.
73. Kehry MR. CD40-mediated signaling in B cells: balancing cell survival, growth, and death. J Immunol. 1996;156:2345-2348.
74. Stout RD, Suttles J. The many roles of CD40 in cell-mediated inflammatory responses. Immunol Today. 1996;17:487-492.
75. van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol. 1997;9:330-337.
76. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16:111-135.
77. Vogel LA, Noelle RJ. CD40 and its crucial role as a member of the TNFR family. Semin Immunol. 1998;10:435-442.
78. Craxton A, Otipoby KL, Jiang A, Clark EA. Signal transduction pathways that regulate the fate of B lymphocytes. Adv Immunol. 1999;73:79-152.
79. Karras JG, Wang Z, Huo L, Frank DA, Rothstein TL. Induction of STAT protein signaling through the CD40 receptor in B lymphocytes: distinct STAT activation following surface Ig and CD40 receptor engagement. J Immunol. 1997;159:4350-4355.
80. Lee HH, Dadgostar H,Cheng Q, Shu J, Cheng G. NF-κB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci U S A. 1999;96:9136-9141.
81. Nakano H, Sakon S, Koseki H, et al. Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation. Proc Natl Acad Sci U S A. 1999;96:9803-9885.
82. Rothe M, Sarma V, Dixit VM, Goeddel DV. TRAF2-mediated activation of NF-κB by TNF receptor 2 and CD40. Science. 1995;269:1424-1427.